Rubicon Research Acquires Impopharma Canada

January 7, 2020 |

2 min read

As part of its ongoing effort to establish a global development network, Rubicon Research Private Limited, a leading specialty pharmaceutical company, announced the acquisition of Impopharma Canada Limited with operations in Ontario, Canada.

Jan. 7, 2020 12:00 UTC

MUMBAI, India--(BUSINESS WIRE)-- As part of its ongoing effort to establish a global development network, Rubicon Research Private Limited, a leading specialty pharmaceutical company, today announced the acquisition of Impopharma Canada Limited with operations in Ontario, Canada.

Impopharma offers comprehensive drug product formulation and process development, as well as wide-ranging analytical testing services to the pharmaceutical industry, specializing in nasal and pulmonary drug products. Over the next several months, the Company plans to establish development plans for a mix of both internal and external development projects.

“I welcome the Impopharma team to the Rubicon Research family and look forward to building new projects and capabilities together,” said Parag Sancheti, Rubicon’s Chief Executive Officer.

The 13,000 sq. ft. Impopharma site in Concord, near Toronto, has been previously inspected by the U.S. FDA and Health Canada and will be the nasal and pulmonary development Center of Excellence in the Rubicon network.

Impopharma Canada has been merged with Rubicon Research Canada Limited, a wholly owned subsidiary of Rubicon Research Private Limited.

About Rubicon Research

Rubicon is a responsible partner to global healthcare innovators that design and deliver quality products for making patients’ lives healthy and happy. Rubicon also develops and commercializes its own value added formulations in the global market. Rubicon currently has several commercial products in the global market and a pipeline of over 60 products in development or under review. Rubicon holds more than 50 issued patents in drug delivery technologies and with its new R&D center can develop pharmaceutical products across dosage forms. The manufacturing facility located in Ambernath (India) has global regulatory approvals for commercial supply of oral solid dosage forms. Rubicon also has a marketing office based in New Jersey, USA.

Rubicon is a portfolio company of General Atlantic, a global growth equity investor with nearly USD 35 billion in assets under management.

Through its “Grow Together” initiative, Rubicon provides capital and strategic support to seed and early-stage ventures founded by entrepreneurs and innovators in the traditional pharmaceutical domain as well as allied domains involving the application of emerging technologies like artificial intelligence, continuous manufacturing and big data in the pharmaceutical industry, to achieve Rubicon’s key goals of Innovation, Quality and Care.

For additional information, please visit www.rubicon.co.in/venture